Press Releases

WASHINGTON, DC, March 28, 2018 – The Alliance for Regenerative Medicine (ARM) today released the complete agenda for its upcoming sixth annual Cell & Gene Therapy Investor Day, taking place April 17, 2018 in New York City, NY. This event, co-hosted by Chardan, PNC Healthcare, Raymond James, and Solebury Trout, provides institutional, strategic, and venture investors with unique insight into financing opportunities for cell and gene therapy-based treatment and tools.

BRUSSELS, Belgium and WASHINGTON, DC – March 14, 2018 – The Alliance for Regenerative Medicine (ARM), an international advocacy organization representing the cell and gene therapy and broader regenerative medicine and advanced therapies sector, today published its recommendations for fostering development of and patient access to advanced therapy medicinal products (ATMPs) in Europe. These proposals support and complement the European Medicines Agency’s (EMA) and the European Commission’s (EC) Action Plan on ATMPs, issued October 2017.

WASHINGTON, D.C., March 5, 2018 – The Alliance for Regenerative Medicine (ARM) today announced the release of its 2017 Annual Data Report, offering an in-depth look at trends and metrics for the cell therapy, gene therapy, tissue engineering and broader global regenerative medicine sector.

WASHINGTON, D.C., February 14, 2018 – The Alliance for Regenerative Medicine (ARM) today announced its annual Cell & Gene Therapy Investor Day will take place April 17, 2018 in New York City. This annual meeting provides institutional, strategic, and venture investors with unique insights into financing opportunities for cell and gene therapy-based treatments and tools.

WASHINGTON, D.C., January 30, 2018 – The Alliance for Regenerative Medicine (ARM) and the National Association of Managed Care Physicians (NAMCP) Medical Directors Institute announced today the joint release of their recent study of medical director perspectives on value demonstration and reimbursement for regenerative and advanced therapies.

WASHINGTON, DC, January 18, 2018 – The Alliance for Regenerative Medicine (ARM) today announced its eighth annual Advanced Therapies Summit, to be held March 14, 2018 in Amsterdam, the Netherlands.

WASHINGTON, D.C., November 30, 2017 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapies and broader regenerative medicine sector, announced its 2018 Cell & Gene Therapies State of the Industry briefing will take place January 8, 2018 in San Francisco, held in conjunction with Biotech Showcase™ 2018.

WASHINGTON, D.C. – November 21, 2017 – The Alliance for Regenerative Medicine (ARM) released today its most recent quarterly data report, offering an in-depth look at cell therapy, gene therapy, tissue engineering and broader global regenerative medicine sector trends and metrics in the third quarter of 2017.

WASHINGTON, DC, November 16, 2017 – In response to the U.S. FDA’s announcement today regarding its regenerative medicine policy framework, the Alliance for Regenerative Medicine (ARM) has issued the following statement:

LONDON and WASHINGTON, D.C., October 17, 2017 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, along with co-hosts UK BioIndustry Association (BIA) and the Cell and Gene Therapy Catapult, releases the agenda for its annual European Advanced Therapies Investor Day, to be held November 9, 2017 in London.

Pages